How should I compare and transition from Jornay (methylphenidate) to Azstarys (serdexmethylphenidate/dexmethylphenidate) for ADHD treatment, including appropriate dosing and titration?

Azstarys vs Jornay: Comparison and Transition Strategy

Both Azstarys and Jornay PM are extended-release methylphenidate formulations with distinct pharmacokinetic profiles—Azstarys provides morning dosing with 13-hour coverage, while Jornay PM is dosed at night for morning effect—making the choice dependent on when symptom control is needed and tolerability of evening versus morning administration.

Key Pharmacological Differences

Azstarys (serdexmethylphenidate/dexmethylphenidate) combines a prodrug (SDX) with immediate-release dexmethylphenidate, providing rapid onset (0.5 hours) with extended duration up to 13 hours postdose 1, 2. The prodrug design potentially reduces abuse liability through parenteral routes 3.

Jornay PM (methylphenidate) is a delayed-release formulation dosed in the evening (6:30-9:30 PM, typically 8:00 PM) to provide symptom control beginning the next morning 4. This addresses early morning symptoms and school preparation challenges.

Clinical Decision Algorithm

Choose Azstarys when:

• Early morning symptom control is needed immediately upon waking
• Patient/family prefers morning medication administration
• Concern exists about evening medication adherence
• Extended 13-hour coverage is required for after-school activities
• Difficulty swallowing pills (can be sprinkled on applesauce or mixed in water) 1

Choose Jornay PM when:

• Early morning routine difficulties are the primary concern
• Evening dosing improves medication adherence
• Morning medication administration is problematic (school, family schedule)
• Patient experiences significant rebound effects with morning-dosed stimulants

Transition Protocol from Jornay PM to Azstarys

Step 1: Discontinue Jornay PM

• Stop Jornay PM completely; do not overlap medications 1
• Do not convert on a milligram-per-milligram basis—these products have different pharmacokinetic profiles and methylphenidate base compositions 1, 4

Step 2: Initiate Azstarys Dosing

For ages 6-12 years:

• Start: 39.2 mg SDX/7.8 mg d-MPH once daily in the morning
• After 1 week, adjust based on response:
  • Increase to 52.3 mg/10.4 mg (maximum dose) if inadequate response
  • Decrease to 26.1 mg/5.2 mg if tolerability issues
• Maximum: 52.3 mg/10.4 mg once daily 1

For ages 13-17 years and adults:

• Start: 39.2 mg SDX/7.8 mg d-MPH once daily in the morning
• After 1 week, increase to 52.3 mg/10.4 mg based on response
• Maximum: 52.3 mg/10.4 mg once daily 1

Step 3: Titration Timeline

• Assess response weekly during the first month
• If no improvement after appropriate dosage adjustment over one month, discontinue 1
• Monitor for paradoxical symptom aggravation requiring dose reduction 1

Critical Monitoring Parameters

Cardiovascular Assessment (Required Pre-Treatment)

• Careful cardiac history and family history of sudden death or ventricular arrhythmia
• Physical examination focusing on cardiac abnormalities
• Avoid in patients with structural cardiac abnormalities, cardiomyopathy, serious arrhythmia, or coronary artery disease 1

Ongoing Monitoring

• Blood pressure and pulse at each visit (both medications increase these parameters) 1
• Height and weight (decreased appetite occurs in 18.5% with Azstarys) 5
• Sleep patterns (insomnia is common; however, Azstarys showed improved CSHQ sleep scores in most domains over 12 months, with only sleep onset delay worsening) 6
• Tic assessment (evaluate family history and clinical presence before initiating) 1

Safety and Tolerability Profile

Azstarys demonstrated good tolerability in a 12-month study with 60.1% experiencing treatment-emergent adverse events, most commonly:

• Decreased appetite (18.5%)
• Upper respiratory tract infection (9.7%)
• Nasopharyngitis (8.0%)
• Decreased weight (7.6%)
• Irritability (6.7%) 5

No clinically meaningful ECG changes, cardiac events, or blood pressure events led to discontinuation 5. The safety profile is comparable to other methylphenidate products with no unexpected findings 5, 3.

Common Pitfalls to Avoid

1. Do not dose-convert directly: Jornay PM and Azstarys have fundamentally different release mechanisms and cannot be substituted milligram-per-milligram 1, 4

2. Timing matters: Azstarys must be taken in the morning; taking it later reduces evening coverage and may worsen sleep onset 1

3. Food consistency: Advise patients to take Azstarys consistently either with or without food to maintain predictable absorption 1

4. Missed dose management: If Azstarys is missed in the morning, do not double-dose or take late in the day due to sleep interference risk

5. Abuse potential: Both are Schedule II controlled substances; assess abuse risk before prescribing and monitor throughout treatment 1

Efficacy Considerations

Azstarys demonstrated significant improvement in ADHD symptoms with a treatment effect from 1-10 hours postdose in laboratory classroom studies, with post-hoc analysis showing 0.5-13 hour efficacy duration 2. This extended coverage may provide advantages over Jornay PM for patients requiring late afternoon/evening symptom control.

Stimulants remain first-line therapy per guidelines 7, with both Azstarys and Jornay PM representing valid methylphenidate formulation choices based on individual patient needs regarding timing of symptom control 7.